Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06009029

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Locally Advanced Pancreatic Cancer Clinical Trial

Official title:
A Multicenter, Single-arm, Prospective Study of SBRT Combined With Zimberelimab (GLS-010) in Patients With Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Clinical Trial Summary

This trial is designed to investigate the efficacy and safety of patients with locally advanced pancreatic cancer by SBRT combined with Zimberelimab(GLS-010).

Clinical Trial Description

This a prospective, single-arm, multicenter study evaluating the efficacy and safety of stereotactic radiotherapy (SBRT) and Zimberelimab(GLS-010) in patients with pancreatic cancer. The primary endpoint is OS, and the secondary are PFS, ORR,DCR and adverse events. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06009029
Study type Interventional
Source Peking University Third Hospital
Contact Junjie Wang, M.D.
Phone +8613701076310
Email wangjunjie_puth@163.com
Status Not yet recruiting
Phase Phase 2
Start date August 2023
Completion date July 2027
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Completed NCT01628458 - Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT04276857 - Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer N/A
Not yet recruiting NCT05988372 - Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) Phase 2
Completed NCT00744640 - Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma Phase 1/Phase 2
Completed NCT03126435 - EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX Phase 3
Completed NCT02035072 - Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer. Phase 2
Enrolling by invitation NCT01063192 - A Study of Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT06429904 - Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT03885219 - Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT03468335 - 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy Phase 3
Not yet recruiting NCT03443921 - Divestment for Artery-involved Pancreatic Cancer N/A
Recruiting NCT03257033 - Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Phase 3
Completed NCT02578732 - FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial Phase 2
Recruiting NCT04789980 - Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY
Completed NCT00644618 - Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy Phase 3
Recruiting NCT03682289 - Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors Phase 2
Terminated NCT02404363 - Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy Phase 3
Active, not recruiting NCT06353581 - Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX Phase 2
Not yet recruiting NCT03815461 - Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer Phase 2